<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Pharm Assoc (2003)</journal-id><journal-id journal-id-type="iso-abbrev">J Am Pharm Assoc (2003)</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of the American Pharmacists Association : JAPhA</journal-title></journal-title-group><issn pub-type="ppub">1544-3191</issn><issn pub-type="epub">1544-3450</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11402586</article-id><article-id pub-id-type="pmcid-ver">PMC11402586.1</article-id><article-id pub-id-type="pmcaid">11402586</article-id><article-id pub-id-type="pmcaiid">11402586</article-id><article-id pub-id-type="manuscript-id">NIHMS1984831</article-id><article-id pub-id-type="pmid">38604474</article-id><article-id pub-id-type="doi">10.1016/j.japh.2024.102093</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1984831</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1984831</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The association between naloxone claims and proportion of independent vs. chain pharmacies: A longitudinal analysis of naloxone claims in the US</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Freibott</surname><given-names initials="CE">Christina E.</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jalali</surname><given-names initials="A">Ali</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Murphy</surname><given-names initials="SM">Sean M.</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Walley</surname><given-names initials="AY">Alexander Y.</given-names></name><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Linas</surname><given-names initials="BP">Benjamin P.</given-names></name><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jeng</surname><given-names initials="PJ">Philip J.</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bratberg</surname><given-names initials="J">Jeffrey</given-names></name><xref rid="A4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marshall</surname><given-names initials="BDL">Brandon D.L.</given-names></name><xref rid="A5" ref-type="aff">e</xref><xref rid="A6" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zang</surname><given-names initials="X">Xiao</given-names></name><xref rid="A7" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Green</surname><given-names initials="TC">Traci C.</given-names></name><xref rid="A5" ref-type="aff">e</xref><xref rid="A6" ref-type="aff">g</xref><xref rid="A8" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morgan</surname><given-names initials="JR">Jake R.</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib></contrib-group><aff id="A1"><label>a</label>Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, MA, USA</aff><aff id="A2"><label>b</label>Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA</aff><aff id="A3"><label>c</label>Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA</aff><aff id="A4"><label>d</label>The University of Rhode Island, College of Pharmacy, Kingston, RI, USA</aff><aff id="A5"><label>e</label>Brown University School of Public Health, Department of Epidemiology, Providence, RI, USA</aff><aff id="A6"><label>g</label>COBRE on Opioids and Overdose, Rhode Island Hospital, Providence, RI, USA</aff><aff id="A7"><label>h</label>University of Minnesota, School of Public Health, Division of Health Policy and Management, Minneapolis, MN, USA</aff><aff id="A8"><label>i</label>Brandeis University Heller School for Social Policy and Management; Rhode Island Hospital, RI, USA</aff><author-notes><corresp id="CR1">Corresponding Author: Christina E. Freibott, MPH, 715 Albany Street, Talbot Building, Boston, Massachusetts, 02118, <email>freibott@bu.edu</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2024</year></pub-date><pub-date pub-type="epub"><day>10</day><month>4</month><year>2024</year></pub-date><volume>64</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">470807</issue-id><fpage>102093</fpage><lpage>102093</lpage><pub-history><event event-type="nihms-submitted"><date><day>17</day><month>05</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-01 00:25:17.390"><day>01</day><month>07</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1984831.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P1">Expanding access to naloxone through pharmacies is an important policy goal. Our objective was to characterize national county-level naloxone dispensing of chain versus independent pharmacies.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">The primary exposure in our longitudinal analysis was the proportion of chain pharmacies in a county, identified through the US Department of Homeland Security 2010 Infrastructure Foundation-Level Data. We defined counties as having &#8220;higher proportion&#8221; of chain pharmacies if at least 50% of pharmacies were large national chains. The primary outcome was quarter-year (2016Q1&#8211;2019Q2) rate of pharmacy naloxone claims per 100,000 persons from Symphony Health at the county-level. We compared the naloxone dispensing rate between county types using two-sample <italic toggle="yes">t</italic>-tests. We estimated the association between county-level chain pharmacy proportion and rate of naloxone claims using a linear model with year-quarter fixed effects.</p></sec><sec id="S3"><title>Results:</title><p id="P3">Nearly one third of counties (n=946) were higher proportion. Higher proportion counties had a significantly higher rate of naloxone claims across the study period, in 4 of 6 urban-rural classifications, and in counties with and without naloxone access laws. The linear model confirmed that higher proportion counties had a significantly higher rate of naloxone claims, adjusting for urban/rural designation, income, population characteristics, opioid mortality rate, co-prescribing laws and naloxone access laws.</p></sec><sec id="S4"><title>Conclusion:</title><p id="P4">In this national study, we found an association between naloxone dispensing rates and the county-level proportion of chain (versus independent) pharmacies. Incentivizing naloxone dispensing through educational, regulatory, or legal efforts may improve naloxone availability and dispensing rates &#8211; particularly in counties with proportionately high numbers of independent pharmacies.</p></sec></abstract><kwd-group><kwd>naloxone</kwd><kwd>chain pharmacy</kwd><kwd>independent pharmacy</kwd><kwd>dispensing</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>